Aktuelles aus der Forschung

Immunologische Ursachen für sekundäre Autoimmunität unter Alemtuzumab

Alemtuzumab (Lemtrada^®) ist seit Oktober 2013 in Deutschland zur Therapie von Patienten mit aktiver Multipler Sklerose zugelassen. Dieser gegen das Oberflächenmolekül CD52 gerichtete Antikörper führt zu einer antikörper- sowie komplementvermittelten Immunzelldepletion, insbesondere von T- und B-Lymphozyten [1]. Die anschließende Repopulation folgt einem spezifischen Muster: Die Erholung von B-Zellen benötigt 3 Monate, die von CD⁸⁺-T-Zellen 20 Monate und von CD⁴⁺-T-Zellen 35 Monate [2].

• Literatur

• 1 Klotz L, Meuth SG, Wiendl H. Immune mechanisms of new therapeutic strategies in multiple sclerosis – A focus on alemtuzumab. Clin Immunol 2012; 142: 25-30
• 2 Hill-Cawthorne GA, Button T, Tuohy O et al. Long-term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 298-304
• 3 Khoruts A, Fraser JM. A causal link between lymphopenia and autoimmunity. Immunol Lett 2005; 98: 23-31
• 4 King C, Ilic A, Koelsch K et al. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004; 117: 265-277
• 5 Le Saout C, Mennechet S, Taylor N et al. Memory-like CD8+ and CD4+ T cells cooperate to break peripheral tolerance under lymphopenic conditions. Proc Natl Acad Sci U S A 2008; 105: 19414-19419
• 6 Jones JL, Thompson SA, Loh P et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci U S A 2013; 110: 20200-20205
• 7 Hertzenberg D et al. Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. Eur J Immunol 2013; 43: 2078-2088
• 8 Cravens PD et al. The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis. J Neuroinflammation 2013; 10: 67
• 9 Vermersch P, Kappos L, Gold R et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76: 1697-1704
• 10 Kappos L, Bates D, Edan G et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011; 10: 745-758
• 11 Berger JR, Aksamit AJ, Clifford DB et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80: 1430-1438
• 12 Warnke C, von Geldern G, Markwerth P et al. Cerebrospinal Fluid JC Virus Antibody Index for Diagnosis of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. Ann Neurol 2014;